Gaba alpha receptors mediate inhibition of T cell responses

Details Gaba alpha receptors mediate inhibition of T cell responses Gaba alpha receptors mediate inhibition of T cell responses

2000-02-24

2002-02-26

Weddington, Kevin E. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S182000, C514S221000, C514S249000, C514S567000

Reexamination Certificate

active

06350769

ABSTRACT:

BACKGROUND OF THE INVENTION
Many of the cells of the immune system express receptors for neuroactive molecules which modulate immune system function, creating a link between the nervous and immune systems (Nio et al. (1993)
J Immunol
. 150:5281-5288; Torcia et al. (1996)
Cell
85:345-356).
&ggr;-Aminobutyric acid (GABA) is a ubiquitous inhibitory neurotransmitter in the central nervous system (CNS; reviewed in Erdo and Wolff (1990)
J. Neurochem
. 54:363-372; Olsen and Tobin (1990)
Faseb J
. 4:1469-1480; Kaufmnan and Tobin (1993)
Trends Pahrmacol. Sci
. 14:107-109; Macdonald and Olsen (1994)
Ann. Rev. Neurosc
. 17:569-602; and Luddens et al. (1995)
Neuropharmacology
34:245-254). GABA is synthesized from glutamic acid by the enzyme glutamate decarboxylase (GAD; reviewed in Erlander et al. (1991)
Neuron
7:91-100). Outside of the brain, GAD and GABA receptors have been reported in the pancreatic islets, the gastrointestinal tract, ovaries and adrenal medulla (Erdo and Wolff (1990), supra).
There are at least two types of neuronal GABA receptors, GABA
A
and GABA
B
. GABA
A
receptors are ligand-gated ion channels which respond to GABA by opening their integral C1
−
channel (Olsen and Tobin (1990); Macdonald and Olsen (1994); Luddens et al. (1995); all supra). Pharmacologically, muscimol acts as an agonist for GABA
A
receptors and anxiolytic benzodiazepines as well as anesthetic agents (such as pentobarbital) potentiate the opening of the GABA
A
-C1
−
channel. Bicuculline and RU5315 antagonize GABA
A
receptor function and picrotoxin blocks the GABA
A
receptor C1
−
channel (Macdonald and Olsen (1994); and Luddens et al. (1995); both supra). In contrast, GABA
B
receptors are coupled to Ca
2+
or K
+
channels via GTP-binding proteins and are selectively activated by baclofen (Bowery (1993)
Annu. Rev. Pharmacol. Toxicol
. 33:109-147). GABA
B
receptors are insensitive to bicuculline and picrotoxin. The administration of GABA or its agonists peripherally inhibits antibody production and modulates macrophage phagocytosis in vivo (Ratnikov et al. (1982)
Biull. Eksp. Biol. Med
. 94:56-58; and Frangulyan et al. (1986) “Influence of neuroactive amino acids on some indexes of natural immunity” In: Neurohumoral regulation of Immune Homeostasis, Leningrad, Russia).
Many diseases, including allergies and autoimmune diseases, as well as graft rejection, result from a deleterious immune response. For example, more than 30 autoimmune diseases are presently known; these include many which have received much public attention, including myasthenia gravis (MG) and multiple sclerosis (MS). Characteristic of these diseases is the attack by the immune system on the tissues of the victim—these tissue antigens being non-immunogenic in non-diseased individuals because of their tolerance of the immune system to “self.” In autoimmune diseases, this tolerance apparently is compromised, and the tissue of the afflicted subject is treated as an invader—i.e., the immune system sets about destroying this presumed foreign target. Furthermore, graft rejection results from the activation of T lymphocytes and allergic reaction are also due to an exacerbated immune response.
Alternatively, enhancing immune responses is useful for treating a number of diseases and infections. In addition, redirecting the immune response can result in a more efficient immunity against certain diseases. For example, a viral infection will be more efficiently eliminated if the immune response can be redirected from a predominantly antibody response to a protective Th1 cell-mediated response.
There is, therefore, a need in the art for methods to modulate the immune system to treat a variety of diseases. The present invention addresses these and other needs.
SUMMARY OF THE INVENTION
The present invention provides methods of modulating an immune response in a patient. The methods comprise administering an immunomodulatory amount of a compound that binds the GABA binding site within a GABA
A
receptor. The compounds are preferably administered orally, transdermally, intravenously, subcutaneously, or using a pump. The compound used in the method can be either an agonist or an antagonist of GABA. In one embodiment, the methods of the invention are used to down-regulate an immune response and the compound is a GABA agonist. These methods are particularly useful in treating diseases which involve a deleterious immune response such as autoimmune disease, allergy, and graft rejection. The methods may further comprise administering a GABA potentiator. In one embodiment, the potentiator binds to the benzodiazepine binding site within a GABA
A
receptor. In another embodiment, the potentiator binds to the barbiturate binding site within a GABA
A
receptor. In yet another embodiment the potentiator binds to the steroid binding site within a GABA
A
receptor.
The invention also provides methods in which the compound that binds the GABA
A
receptor is a GABA antagonist. These methods are used to enhance an immune response. The methods are particularly useful in enhancing a Th1-mediated immune response. Such methods are useful, for example, in enhancing immune response against certain pathogens such as viruses.


REFERENCES:
patent: 5637617 (1997-06-01), Woodward et al.
patent: 5723462 (1998-03-01), Albaugh et al.
patent: 5925630 (1999-07-01), Upasani et al.
Devoino et al., “Immunomodulating effect of activators and blockers of the GABA-receptor-ionophore complex”, Farmakol. Toksikol. (Moscow) (1988), 51(3), pp. 78-80 (abstract),*
Bergeret et al. (1998) GABA modulates cytotoxicity of immunocompetent cells expressing GABAAreceptor subunitsBiomed. Pharmacother. 52(5): 214-219.
Defeudis et al. (1998) Muscimol and central nervous system gamma-aminobutyric amino acid receptors: studies with ligand binding techniques (1986)in Receptors, vol. 3, Eds. Conn, P.M., Publ. Academic, Orlando, FL.
Ratnikov et al. (1982) Effect of GABA-ergic substances on humoral immunityBiull.Eksp.Biol.Med.94:56-58.
International Search Report mailed May 30, 2000 for International Application No. PCT/US00/04921.

Affiliated with

Also associated with

Rating

Gaba alpha receptors mediate inhibition of T cell responses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Gaba alpha receptors mediate inhibition of T cell responses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gaba alpha receptors mediate inhibition of T cell responses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2964429